Aytu BioPharma, Inc. (AYTU) Cash Flow Statement
Where AYTU’s cash came from and went, FY2026
June 30, 2026 · U.S. dollars- Cash from operations
- $3.3M
- Capital expenditures
- $29,000 0.1% of revenue
- Free cash flow
- $3.3M 5.6% margin
- Returned to shareholders
- —
- Change in cash
- −$4.6M cash at year-end $26.3M
Cash from operations
$3.3M
Capital expenditures
−$29,000
Net borrowing (repayment)
−$4.8M
Other financing
−$3.0M
Change in cash
−$4.6M
Drawn to scale: where the cash came from and how it was used. Hover for values.
AYTU operating cash flow, capex and free cash flow
Operating cash flowCapital expendituresFree cash flowFCF margin (right axis)
AYTU cash flow trends, FY2017–FY2026
| Metric | Trend | Then | Latest | Change |
|---|---|---|---|---|
| Operating cash flow | −$13.8MFY2017 | $3.3MFY2026 | — | |
| Capital expenditures | $111,608FY2017 | $29,000FY2026 | −13.9%/yr | |
| Free cash flow | −$13.9MFY2017 | $3.3MFY2026 | — | |
| Free cash flow margin | −432.7%FY2017 | 5.6%FY2026 | +438.4 pts | |
| Stock-based compensation | $2.5MFY2017 | $691,000FY2026 | −13.3%/yr | |
| Share buybacks (net) | $0FY2017 | $0FY2020 | — | |
| Capex / revenue | 3.5%FY2017 | 0.1%FY2026 | −3.4 pts |
Change is the average annual growth (CAGR) or the difference between the first and latest year.
AYTU cash flow by activity
OperatingInvestingFinancingChange in cash
AYTU net income vs operating cash flow
Net incomeOperating cash flow
Operating cash flow above net income usually means earnings are backed by cash (depreciation and stock-based pay are non-cash expenses).
AYTU cash flow statement
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating activities | ||||||||||
| Net income | −$14.3M | −$13.6M | −$15.8M | −$17.1M | −$108.8M | −$58.3M | −$13.6M | −$27.1M | −$10.2M | −$22.5M |
| Depreciation & amortization | $3.9M | $5.4M | $6.7M | $8.8M | $10.1M | $9.2M | $5.7M | $2.7M | $2.6M | $4.4M |
| Stock-based compensation | $691,000 | $576,000 | $2.4M | $6.0M | $5.2M | $3.6M | $1.1M | $1.0M | $348,515 | $2.5M |
| Change in working capital | $5.8M | −$5.7M | −$4.7M | −$5.8M | −$10.9M | $1.7M | −$12.6M | −$210,199 | −$718,809 | −$1.0M |
| Other non-cash items | $7.1M | $11.4M | $10.0M | $2.9M | $75.4M | $17.9M | −$8.9M | $9.8M | −$8.0M | $2.9M |
| Cash from operating activities | $3.3M | −$1.9M | −$1.4M | −$5.1M | −$28.8M | −$26.0M | −$28.4M | −$13.8M | −$15.9M | −$13.8M |
| Investing activities | ||||||||||
| Capital expenditures | −$29,000 | −$3.2M | −$329,000 | $0 | −$2.3M | −$2.3M | −$5.8M | −$59,848 | −$74,707 | −$111,608 |
| Investments (net) | — | −$2.6M | −$329,000 | −$117,000 | −$3.2M | −$2.8M | −$5.7M | −$1.1M | −$484,292 | −$3.5M |
| Acquisitions & other investing | $0 | $3.2M | $329,000 | $0 | $2.3M | $2.3M | $5.8M | $59,848 | $74,707 | $111,608 |
| Cash from investing activities | −$29,000 | −$2.6M | −$329,000 | −$117,000 | −$3.2M | −$2.8M | −$5.7M | −$1.1M | −$484,292 | −$3.5M |
| Financing activities | ||||||||||
| Share repurchases & issuance (net) | — | — | — | — | — | — | $87.3M | $15.6M | $25.4M | $11.6M |
| Net borrowing (repayment) | −$4.8M | $6.7M | −$1.9M | −$2.3M | −$5.2M | −$3.7M | −$16.2M | $5.0M | $5.0M | $5.0M |
| Shares issued | $0 | $14.8M | $3.5M | $15.6M | $11.7M | $45.1M | $65.7M | $15.2M | $0 | $0 |
| Other financing | −$3.0M | −$6.1M | −$2.8M | −$4.4M | −$4.9M | −$11.0M | −$65.7M | −$16.7M | −$7.8M | −$6.4M |
| Cash from financing activities | −$7.9M | $15.4M | −$1.3M | $8.9M | $1.5M | $30.3M | $71.1M | $19.1M | $22.7M | $10.2M |
| Summary | ||||||||||
| Net change in cash | −$4.6M | $10.9M | −$3.0M | $3.6M | −$30.5M | $1.6M | $37.0M | $4.2M | $6.2M | −$7.2M |
| Cash at end of period | $26.3M | $31.0M | $20.0M | $23.0M | $19.4M | $49.9M | $48.3M | $11.3M | $7.1M | $877,542 |
| Free cash flow | $3.3M | −$5.2M | −$1.7M | −$5.1M | −$28.8M | −$26.0M | −$28.4M | −$13.9M | −$16.0M | −$13.9M |
| Free cash flow margin | 5.6% | −7.8% | −2.6% | −4.8% | −29.8% | −39.6% | −102.7% | −189.8% | −437.6% | −432.7% |
| Capex / revenue | 0.1% | 4.9% | 0.5% | 0.0% | 2.4% | 3.6% | 21.2% | 0.8% | 2.0% | 3.5% |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating activities | ||||||||||||
| Net income | −$15,000 | −$5.6M | −$10.6M | $2.0M | −$19.9M | $4.0M | $788,000 | $1.5M | −$4.6M | −$2.9M | −$220,000 | −$8.1M |
| Depreciation & amortization | $1.1M | $1.1M | $885,000 | $803,000 | $1.3M | $1.3M | $1.2M | $1.4M | $1.9M | $1.5M | $1.8M | $1.8M |
| Stock-based compensation | $146,000 | $148,000 | $283,000 | $114,000 | $113,000 | $139,000 | $151,000 | $173,000 | $242,000 | $699,000 | $707,000 | $725,000 |
| Change in working capital | $3.7M | −$1.8M | $4.0M | −$23,000 | $1.6M | −$9.8M | $3.2M | −$854,000 | −$1.6M | $417,000 | −$3.7M | −$1.4M |
| Other non-cash items | −$534,000 | $2.0M | $9.1M | −$3.5M | $19.6M | −$2.1M | −$2.4M | −$3.4M | $3.2M | −$16,000 | $1.3M | $6.7M |
| Cash from operating activities | $4.4M | −$4.2M | $3.7M | −$618,000 | $2.8M | −$6.5M | $2.9M | −$1.2M | −$788,000 | −$254,000 | −$135,000 | −$211,000 |
| Investing activities | ||||||||||||
| Capital expenditures | −$12,000 | $0 | −$17,000 | $0 | −$17,000 | −$69,000 | −$6,000 | −$136,000 | −$329,000 | $0 | $0 | $0 |
| Investments (net) | — | — | — | $0 | −$3.0M | −$69,000 | $145,000 | $381,000 | −$34,000 | −$45,000 | −$174,000 | −$76,000 |
| Acquisitions & other investing | $0 | — | $0 | — | $17,000 | $69,000 | $6,000 | $136,000 | $329,000 | $0 | $0 | $0 |
| Cash from investing activities | −$12,000 | — | −$17,000 | — | −$3.0M | −$69,000 | $145,000 | $381,000 | −$34,000 | −$45,000 | −$174,000 | −$76,000 |
| Financing activities | ||||||||||||
| Net borrowing (repayment) | −$4.8M | $872,000 | −$6.3M | $5.3M | $428,000 | $5.6M | −$723,000 | $1.4M | — | — | — | −$370,000 |
| Shares issued | $0 | $0 | $0 | $0 | $14.8M | $0 | $0 | $0 | $3.4M | $0 | $86,000 | $0 |
| Other financing | $0 | $0 | $0 | −$3.0M | −$2.3M | −$1.3M | −$2.0M | −$500,000 | −$2.3M | $530,000 | −$212,000 | −$2.4M |
| Cash from financing activities | −$4.8M | $872,000 | −$6.3M | $2.3M | $13.0M | $4.3M | −$2.8M | $911,000 | $1.1M | $530,000 | −$126,000 | −$2.7M |
| Summary | ||||||||||||
| Net change in cash | −$407,000 | −$3.3M | −$2.6M | $1.7M | $12.8M | −$2.2M | $290,000 | $102,000 | $246,000 | $231,000 | −$435,000 | −$3.0M |
| Cash at end of period | $26.3M | $26.7M | $30.0M | $32.6M | $31.0M | $18.2M | $20.4M | $20.1M | $20.0M | $19.8M | $19.5M | $20.0M |
| Free cash flow | $4.4M | −$4.2M | $3.7M | −$618,000 | $2.8M | −$6.5M | $2.9M | −$1.3M | −$1.1M | −$254,000 | −$135,000 | −$211,000 |
| Free cash flow margin | 27.3% | −33.7% | 24.1% | −4.4% | 18.4% | −35.4% | 17.9% | −8.0% | −6.2% | −1.8% | −0.7% | −1.2% |
| Capex / revenue | 0.1% | 0.0% | 0.1% | 0.0% | 0.1% | 0.4% | 0.0% | 0.8% | 1.8% | 0.0% | 0.0% | 0.0% |
| Operating cash flow / net income | — | — | — | −0.31 | — | −1.62 | 3.69 | −0.81 | — | — | — | — |
Negative numbers are cash paid out. Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported; data from EODHD.
AYTU cash generation
In fiscal 2026 (ended June 30, 2026), Aytu BioPharma generated $3.3 million of cash from operations and spent $0.0 million on capital expenditures, leaving free cash flow of $3.3 million, 5.6% of revenue. Cash and equivalents fell by $4.6 million over the year.
Related: AYTU income statement, AYTU balance sheet. See the AYTU stock overview for the latest quote and news.
AYTU cash flow FAQ
What is Aytu BioPharma's free cash flow?
Aytu BioPharma's free cash flow was $3.3 million in fiscal 2026: $3.3 million of operating cash flow minus $0.0 million of capital expenditures It was -$5.2 million a year earlier..
How much cash does Aytu BioPharma generate from operations?
Aytu BioPharma generated $3.3 million of cash from operating activities in fiscal 2026.
How much does Aytu BioPharma spend on capital expenditures?
Aytu BioPharma spent $0.0 million on capital expenditures in fiscal 2026, 0.1% of revenue, compared with $3.2 million the year before.